Metastatic colorectal cancer - Pipeline Insight, 2024

This “Metastatic colorectal cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in Metastatic colorectal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Metastatic colorectal cancer Understanding

Metastatic colorectal cancer: Overview

Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it originally started. So colorectal cancer that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer. The most common site of metastases for colon or rectal cancer is the liver. Colorectal cancer cells may also spread to the lungs, bones, brain or spinal cord. Metastatic colorectal cancer is different from recurrent colorectal cancer. Recurrent colorectal cancer is cancer that returns to the same part of the colon or rectum after treatment, rather than spreading to other parts of the body. Treatment options may vary depending on where the cancer has spread, but they may include surgery, radiation therapy, chemotherapy and/or targeted therapy.

Metastatic colorectal cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic colorectal cancer pipeline landscape is provided which includes the disease overview and Metastatic colorectal cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic colorectal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic colorectal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic colorectal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic colorectal cancer.

Metastatic colorectal cancer Emerging Drugs Chapters

This segment of the Metastatic colorectal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic colorectal cancer Emerging Drugs

Adagrasib (MRTX849): Mirati Therapeutics Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation. Adagrasib is being explored as a monotherapy as well as in combination with other anticancer drugs. The goal is to optimize efficacy and prevent treatment resistance, ensuring these potentially promising combination therapies can help patients throughout the course of their treatment journey. Extensive preclinical studies showed that combining adagrasib with a broad range of therapies, including PD-1, SHP2, Pan-EGFR, CDK 4/6, and SOS1 inhibitors, resulted in even more robust anti-tumor activity.

QL-1203: Qilu Pharmaceutical QL-1203, is an investigational drug being developed by Qilu Pharmaceutical. QL-1203, acts as an epidermal growth factor receptor modulator. It belongs to the class of monoclonal antibodies. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Metastatic colorectalcancer.

ZN-c3: Zentalis Pharmaceuticals ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1/2 clinical trial in patients with Metastatic Colorectal Cancer. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer.

Metastatic colorectal cancer: Therapeutic Assessment

This segment of the report provides insights about the different Metastatic colorectal cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Metastatic colorectal cancer

There are approx. 130+ key companies which are developing the therapies for Metastatic colorectal cancer. The companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

Phases

This report covers around 140+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic colorectal cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Metastatic colorectal cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic colorectal cancer drugs.

Metastatic colorectal cancer Report Insights

• Metastatic colorectal cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Metastatic colorectal cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Metastatic colorectal cancer drugs?
• How many Metastatic colorectal cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic colorectal cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Metastatic colorectal cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Metastatic colorectal cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mirati Therapeutics
• Shanghai Zhangjiang Biotechnology Limited Company
• Genor Biopharma Co., Ltd.
• Menarini Group
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Arcus Biosciences, Inc.
• SFJ Pharmaceuticals
• Merck Serono
• Sumitomo Pharma Co., Ltd.
• Immunovative Therapies, Ltd.
• Cardiff Oncology
• Symphogen A/S
• Genentech
• Qilu Pharmaceutical Co., Ltd.
• Henlix Biotech
• Scandion Oncology A/S
• Aadi Bioscience, Inc.
• Novartis
• Roche
• Boehringer Ingelheim
• Isofol Medical
• Treos Bio
• Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Elevar Therapeutics
• Shanghai Henlius Biotech

Key Products

• Adagrasib (MRTX849)
• CMAB009
• Geptanolimab
• MEN1611
• Anlotinib
• Etrumadenant
• EMD 525797
• BBI608
• AlloStim
• Onvansertib
• Sym004
• Inavolisib
• QL1203
• HLX10
• SCO-101
• ABI-009
• NIS793
• RO7122290
• BI 1701963
• Arfolitixorin
• PolyPEPI1018
• SHR-1701
• Rivoceranib

This product will be delivered within 1-3 business days.